A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry
Tekijät: Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, Beitner-Johnson D, Benistan K, Cabrera G, Charrow J, Kantola I, Linhart A, Nicholls K, Niemann M, Scott CR, Sims K, Waldek S, Warnock DG, Strotmann J
Kustantaja: NATURE PUBLISHING GROUP
Julkaisuvuosi: 2013
Journal: Genetics in Medicine
Tietokannassa oleva lehden nimi: GENETICS IN MEDICINE
Lehden akronyymi: GENET MED
Numero sarjassa: 12
Vuosikerta: 15
Numero: 12
Aloitussivu: 958
Lopetussivu: 965
Sivujen määrä: 8
ISSN: 1098-3600
DOI: https://doi.org/10.1038/gim.2013.53
Tiivistelmä
Conclusion: Agalsidase-beta treatment for >= 2 years may improve or stabilize left-ventricular mass in men with Fabry disease. Further investigations may determine whether early intervention and stabilization of LVM are correlated with clinical outcomes.
Conclusion: Agalsidase-beta treatment for >= 2 years may improve or stabilize left-ventricular mass in men with Fabry disease. Further investigations may determine whether early intervention and stabilization of LVM are correlated with clinical outcomes.